Factors related to sexual function in transgender individuals

Barcelos T1, Franceschini S2, Brito L3, Jorge C2, Lara L2

Research Type

Pure and Applied Science / Translational

Abstract Category

Transgender Health

Abstract 309
Transgender Health, Male Sexual Dysfunction, Urethra
Scientific Podium Short Oral Session 38
Friday 29th September 2023
16:00 - 16:07
Room 101
Hormone Therapy Gender Affirming Surgery Sexual Dysfunction Transgender
1. Reference Center of womens health, 2. University of Sao Paulo, 3. University of Campinas
Presenter
Links

Abstract

Hypothesis / aims of study
Little is known about the sexual function (SF) of transgender (trans) people. Most of the studies use questionnaires that are validated for cisgender individuals.¹ This study aimed to evaluate factors related to SF in trans-men and trans-women.
Study design, materials and methods
Trans individuals who were outpatients at our gender incongruence (GI) center for follow-up of gender affirming hormone therapy with age ranging 27 to 30 years old were invited to participate in this cross-sectional study. Clinical data were collected from the medical records. The scale female sexual function index (FSFI) was administered to all trans-females (n=50) and all trans-males (n=58). The FSFI questionnaire has 19 questions grouped in six domains (desire, arousal, lubrification, orgasm, pain, and satisfaction). The score ≤ 26.55 is a risk for sexual dysfunction². Also, each participant also responded to a semi-structured questionnaire that assessed feelings regarding being transgender in Brazil and satisfaction with sexual life. The Hospital Anxiety and Depression Scale (HAD) questionnaire was used to assess the individual’s mood. The HAD has 14 items divided in two subscales: seven to assess anxiety, and seven to assess depression. The cutoff score for anxiety and depression is ≥ 8 and ≥ 9, respectively³. A logistic regression model was constructed to estimate the relationships of different variables with FSFI scores, and the results were reported as odds ratios (ORs).
Results
There were 108 participants, 58 (53.70%) trans men, and 50 (46.30%) trans women. These two groups were similar in most characteristics, but differed in comorbidities, body mass index (BMI), duration of relationship, number of sexual partners, and frequency of sexual intercourse.
Analysis of the FSFI scores showed that 32 trans men (55.2%) and 41 trans women (82.0%) had total FSFI scores of 26.55 or less. Relative to trans women, the trans men had a significantly better total FSFI score and in the domains of arousal, lubrication, orgasm, and satisfaction (all P < 0.01). 
The semi-structured analysis of sexual satisfaction showed that 17 (28.80%) trans men were very dissatisfied or  dissatisfied, and 21 (30%) were very dissatisfied or dissatisfied
Interpretation of results
The Table 1 shows the results of the estimate of the logistic regression model with univariate analysis for being risk of SDF and evidences that age, BMI, years of study, ethnicity, marital status, sexual orientation, GAS, satisfaction with gender affirming hormone therapy, and feeling discriminated do not predispose SDF. While the gender, therefore being women, dissatisfaction with body appearance, having risk for anxiety and depression are factors of risk of sexual dysfunction.
A multivariate analysis of these data showed that being a trans woman (OR: 0.242, 95% CI: 0.095, 0.615) and having score of risk for depression in the HADS (OR: 0.22, 95% CI: 0.055, 0.88) were significant risk factors for SDF (Table 2).
Concluding message
Our FSFI results indicated a high risk of SDF in trans women (82%), and that more than half of trans men also had a risk for SDF. However, these rates of SDF were lower in our semi-structured questionnaire. This discrepancy suggests the need for more specific validated questionnaires that more adequately assess the sexual function of trans individuals. It also demonstrates that validated questionnaires that were developed for cis-gender people are inappropriate for assessing sexual function of trans-gender people. Nonetheless, we found that status as a trans-female and depression increased the risk for SDF in our population.
Figure 1 Table 1. Crude odds ratio estimates followed by the respective 95% confidence intervals of the exploratory variables in relation to the FSFI outcome (score ≤ 26.55)
Figure 2 Table 2. Adjusted odds ratio estimates followed by the respective 95% confidence intervals of the exploratory variables in relation to the FSFI outcome (score ≤ 26.55)
References
  1. Barcelos TMR, Ferreira CHJ, Lerri MR, Brito LGO, de Sá MFS, de Sá ACS, da Silva Lara LA. Sexual function of transgender women after gender affirming surgery: A mini review. Clin Anat. 2022 Jul;35(5):560-570. doi: 10.1002/ca.23863. Epub 2022 Apr 2. PMID: 35334140.
  2. Rosen, C. Brown, J. Heiman, S. Leib R. The Female Sexual Function Index (FSFI): A Multidimensional Self-Report Instrument for the Assessment of Female Sexual Function. Journal of Sex & Marital Therapy. 2000;26(2):191-208. doi:10.1080/009262300278597
  3. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361-370. doi:10.1111/j.1600-0447.1983.tb09716.x
Disclosures
Funding NONE Clinical Trial No Subjects Human Ethics Committee Research Ethics Committee of the Clinical Hospital of Ribeirão Preto Medical School (RPMS) Helsinki Yes Informed Consent Yes
Citation

Continence 7S1 (2023) 101026
DOI: 10.1016/j.cont.2023.101026

20/11/2024 01:05:11